Yoda et al. conducted another study, where they specifically investigated sequential ALK inhibitor therapy and its relation to lorlatinib-resistant compound ALK mutations in lung cancer featuring ALK-positivity [74]. This evidence concerns the gene ALK and lung carcinoma.